NEW YORK ( TheStreet) -- XenoPort ( XNPT) was the biggest gainer among small-caps Thursday after the biotech company won approval for its first drug Horizant used to treat moderate-to-severe restless leg syndrome. The stock was up 66% at $10.64 on volumes of more than 17 million shares.

Shares of Immunogen ( IMGN) jumped 21% to $11.28 after an experimental breast cancer drug that it is developing with Roche was found to be more successful than the standard treatment in a mid-stage study.

Retail stocks were buzzing after stronger-than-expected same-store sales data. Pier 1 Imports ( PIR) saw its shares climb 9% to $11.52 after it reported better-than-expected results. Sales rose 7.7% to $426.6 million, beating the analysts' average estimate of $425.6 million. Sales at stores open at least a year rose 8.9%.

Rite Aid ( RAD) was up 6.6% to $1.13 after it posted a narrower-than-expected loss and its sales stabilized. The company said it may narrow its losses significantly in fiscal 2012, and forecasted stronger revenue than analysts expected.

Express ( EXPR) shares were climbing 4.5% to $20.23. The company announced the pricing of the offering of 19,800,000 common shares by certain stockholders at $19 a share, reflecting an upsize from the previously announced offering of 16.5 million shares.

Shares of Intersil ( ISIL) rose rising 5.8% to $14.09. Stocks of semiconductor companies were climbing after Texas instruments (TXN) said earlier this week it will acquire National Semiconductor ( NSM) for $6.5 billion.

Shares of Rare Element Resources ( REE) and Avalon Rare Metals ( AVL) were soaring 10.7% and 4.9%, respectively. A bill was introduced Wednesday that would benefit U.S. rare earth miners, according to a release from the U.S. Magnetic Materials Association.

--Written by Shanthi Bharatwaj in New York

>To contact the writer of this article, click here: Shanthi Bharatwaj.

>To follow the writer on Twitter, go to http://twitter.com/shavenk.

>To submit a news tip, send an email to: tips@thestreet.com.
Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.

If you liked this article you might like

Ardelyx Has Big Potential

Ardelyx Has Big Potential

Biotech M&A Waking Up After Long Nap

Biotech M&A Waking Up After Long Nap

Xenoport's Cost-Cutting Tactics Lead to Buyout With Hefty Premium

Here's Why XenoPort (XNPT) Stock is Continuing to Surge Today

Trending Tickers: XNPT, OLED, MON, TPUB

Trending Tickers: XNPT, OLED, MON, TPUB